Please login to the form below

Not currently logged in
Email:
Password:

BioAlliance announces managerial changes

Dr Gilles Avenard resigns as board member and deputy CEO in charge of R&D, while Dr Pierre Attali becomes CEO

BioAlliance Pharma, a company dedicated to the supportive care and treatment of cancer patients, has announced changes to its management structure.

Dr Gilles Avenard has resigned as board member and deputy CEO in charge of R&D, while Dr Pierre Attali, who has been serving BioAlliance Pharma as chief medical officer for several years, has been appointed as the company's CEO.

Dominique Costantini, CEO of BioAlliance Pharma commented: "I am delighted by Pierre Attali's appointment. His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the company and its commercial partners when preparing the next launches of BioAlliance's products."

4th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics